Avalyn Pharma Inc. (AVLN) vs Novavax, Inc. (NVAX)

Avalyn Pharma Inc. and Novavax, Inc. are both Biotechnology companies. Avalyn Pharma Inc. and Novavax, Inc. are of similar size ($1.3B and $1.2B). Avalyn Pharma Inc. has the higher net margin (0.00% vs −18.6%) and the lower return on invested capital (−127.6% vs 0.00%). Across the 10 metrics below, Avalyn Pharma Inc. leads on 6 and Novavax, Inc. on 4.

Valuation

Metric AVLN NVAX Biotechnology median
P/E n/m n/m 10.01
P/S n/m 3.19 9.02
P/B 3.34 n/m 2.13
Price to free cash flow n/m n/m 24.99
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 2.39 9.01
Earnings yield (157.17%) (5.79%) (34.01%)
Free cash flow yield (8.11%) (18.74%) (24.62%)

Profitability

Metric AVLN NVAX Biotechnology median
Gross margin — 78.01% 70.18%
Operating margin 0.00% (21.23%) 0.00%
Net margin 0.00% (18.64%) 0.00%
Free cash flow margin 0.00% (59.25%) 0.00%
Return on equity 0.00% 41.08% (50.72%)
Return on assets 0.00% (7.42%) (45.56%)
Return on invested capital (127.60%) 0.00% 0.00%

Growth

Metric AVLN NVAX Biotechnology median
Revenue growth (TTM) — (61.33%) 7.42%
EPS growth (last fiscal year) — 309.76% 29.36%
Revenue growth, 5-year CAGR — 18.76% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVLN NVAX Biotechnology median
Debt to equity 0.04 (1.35) 0.00
Current ratio 25.76 2.15 4.72
Net debt to EBITDA — (1.04) 1.01

Dividend

Metric AVLN NVAX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AVLN NVAX Biotechnology median
Market cap 1.24b 1.31b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack